Elevate Credit (ELVT) Shares March Higher, Can It Continue?

Zacks Equity Research
Updated
Verizon and AT&T recently reported third-quarter results, putting focus on telecom ETFs.

As of late, it has definitely been a great time to be an investor in Elevate Credit, Inc. ELVT. The stock has moved higher by 24% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider ELVT’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as ELVT has earned itself a Zacks Rank #1 (Strong Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Elevate Credit, Inc. (ELVT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research